We have expanded our CancerPrecision® diagnostics service with the option for additional RNA-based gene expression analysis, providing an even more comprehensive molecular understanding of solid tumors.
CeGaT’s CancerPrecision® service provides comprehensive genomic tumor profiling to support targeted therapy decisions by identifying clinically relevant variants and biomarkers. With the new option for transcriptome sequencing, we now provide the ability to analyze gene expression across all tumor-relevant genes.
Gene expression analysis refines tumor diagnostics
Deviations in gene expression affect tumor development and treatment response, making gene expression analysis crucial for diagnosis, prognosis, and personalized therapy. Detecting overexpression or reduced expression can confirm DNA-based findings, like low-level amplifications or promoter variant effects, and suggest additional therapeutic options. Gene expression changes can also be detected without identifying an associated mutation at the DNA level. These insights guide analyses like immunohistochemical staining and reveal actionable targets. We identify deviations in gene expression by comparing a case’s results with our extensive in-house cohort of tumor transcriptomes, which has been built up over the last nine years.
CeGaT’s Comprehensive Tumor Diagnostics
CancerPrecision® forms the DNA-based cornerstone of CeGaT’s advanced tumor diagnostics. CancerFusionRx® and a gene expression analysis are two RNA-based options leading to even more treatment options. CancerAdvice® provides concrete treatment recommendations:
CancerPrecision®:
- sequencing and analysis of more than 700 genes and fusions in more than 30 genes
- high sequencing coverage of 500x – 1,000x: reliable detection of therapy-relevant variants in subclones
- sequencing of tumor and normal tissue – accurate detection of somatic variants
- TMB, MSI, and viral infection (HPV/EBV/MCV/CMV) – biomarkers for immunotherapies
- HRD score – biomarker for PARP inhibition
- analysis of SNVs, insertions, and deletions (indels), translocations, and CNVs
- besides tumor-specific mutations also disease-causing and therapy-relevant germline variants are reported
- selected pharmacogenetically variants – necessary for drug dose adjustment
- detection of mosaic variants: CHIP (Clonal Hematopoiesis of Indeterminate Potential)
- medical report contains a list of all eligible drugs, with EMA and/or FDA approval
Option 1: CancerFusionRx®
Detection of gene fusions:
- RNA-based
- over 150 genes for fusion detection
- over 120 exon-exon-specific enrichments targeting recurrent breakpoints
- medical report lists all eligible drugs with EMA and/or FDA approval
Option 2: Gene Expression Analysis
Analysis of gene expressions:
- RNA-based
- assessing gene expression of tumor relevant genes
- results can verify DNA findings on RNA level, provide recommendations for further analysis (such as IHC staining), and identify potential therapeutic targets
- medical report contains comprehensive table with the expression values of selected genes, additionally shown as violin graphs to provide visual context
CancerAdvice®
Detailed tumor therapy recommendation:
- summary of all relevant tumor profiling findings
- considering all information available: results of CeGaT’s tumor diagnostics, IHC results, therapeutic history of the patient, etc.
- recommendation of a treatment strategy for the patient’s cancer